Abeona Therapeutics Inc. (NASDAQ:ABEO) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued on Thursday.

According to Zacks, “Abeona Therapeutics, Inc. is engaged in developing and delivering gene therapy and plasma-based products for rare diseases. Abeona Therapeutics Inc., formerly known as PlasmaTech Biopharmaceuticals, Inc., is based in Dallas, United States. “

ABEO has been the subject of a number of other reports. Maxim Group set a $17.00 price target on Abeona Therapeutics and gave the stock a “buy” rating in a report on Wednesday, August 16th. Jefferies Group LLC reaffirmed a “buy” rating and issued a $28.00 price target on shares of Abeona Therapeutics in a report on Wednesday. HC Wainwright reaffirmed a “buy” rating and issued a $30.00 price target (up from $20.00) on shares of Abeona Therapeutics in a report on Monday, October 16th. Citigroup Inc. started coverage on Abeona Therapeutics in a research note on Tuesday, October 10th. They set a “buy” rating and a $32.00 price objective for the company. Finally, Cantor Fitzgerald lifted their price objective on Abeona Therapeutics from $21.00 to $34.00 and gave the company an “overweight” rating in a research note on Wednesday, October 11th. Two equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $26.10.

Abeona Therapeutics (NASDAQ:ABEO) remained flat at $$16.15 during trading on Thursday. The company’s stock had a trading volume of 501,000 shares, compared to its average volume of 623,707. Abeona Therapeutics has a one year low of $4.05 and a one year high of $22.75.

Abeona Therapeutics (NASDAQ:ABEO) last posted its quarterly earnings results on Wednesday, November 15th. The biopharmaceutical company reported ($0.13) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.18) by $0.05. Abeona Therapeutics had a negative return on equity of 27.69% and a negative net margin of 2,946.58%. The firm had revenue of $0.22 million during the quarter, compared to analyst estimates of $0.22 million. equities analysts predict that Abeona Therapeutics will post -0.66 EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Abeona Therapeutics Inc. (ABEO) Stock Rating Lowered by Zacks Investment Research” was posted by American Banking News and is the property of of American Banking News. If you are reading this report on another site, it was stolen and republished in violation of international trademark and copyright legislation. The legal version of this report can be read at https://www.americanbankingnews.com/2017/11/23/abeona-therapeutics-inc-abeo-stock-rating-lowered-by-zacks-investment-research.html.

Large investors have recently bought and sold shares of the stock. Bank of New York Mellon Corp boosted its stake in Abeona Therapeutics by 138.5% during the second quarter. Bank of New York Mellon Corp now owns 99,996 shares of the biopharmaceutical company’s stock valued at $640,000 after buying an additional 58,067 shares during the period. Schwab Charles Investment Management Inc. bought a new stake in Abeona Therapeutics during the second quarter worth about $264,000. Goldman Sachs Group Inc. lifted its stake in Abeona Therapeutics by 869.7% during the first quarter. Goldman Sachs Group Inc. now owns 116,000 shares of the biopharmaceutical company’s stock worth $580,000 after purchasing an additional 104,038 shares during the last quarter. Ardsley Advisory Partners lifted its stake in Abeona Therapeutics by 33.3% during the second quarter. Ardsley Advisory Partners now owns 60,000 shares of the biopharmaceutical company’s stock worth $383,000 after purchasing an additional 15,000 shares during the last quarter. Finally, Teachers Advisors LLC bought a new stake in Abeona Therapeutics during the second quarter worth about $284,000. 36.34% of the stock is owned by institutional investors.

About Abeona Therapeutics

Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel gene therapies for life-threatening rare genetic diseases. The Company’s lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB).

Get a free copy of the Zacks research report on Abeona Therapeutics (ABEO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Abeona Therapeutics (NASDAQ:ABEO)

Receive News & Ratings for Abeona Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.